Dr. Dennis Slamon's honor in precision medicine masks the crushing reality of high drug costs and access inequality in modern healthcare.
The hype around BBB-crossing antibody technology masks a brutal reality. Is this truly a breakthrough, or just another pharmaceutical mirage in the fight against neurodegeneration?
The convergence of healthcare and artificial intelligence isn't just hype; it's a seismic shift threatening incumbents. Discover the hidden winners in the new pharma landscape.
Behind the glossy veneer of 'translating science' in Cystic Fibrosis, we dissect the hidden economic winners and the ethical cost of next-gen therapies.
The Greenland shark holds the secret to longevity, but the real story is the biotech gold rush this discovery triggers. Dive into the science.
Forget dieting. A new study promises safer cell calorie burning, but the real story behind this metabolic breakthrough is the looming shadow of Big Pharma.
OPKO Health is at J.P. Morgan, but the real story isn't the conference; it's the silent battle for solvency in the volatile biotech sector.
The recent formation of Sinaptica Therapeutics' Scientific Advisory Board isn't just good PR; it's a telltale sign of high-stakes **biotech investment** pressure and the race for **drug development** success.
BioRender's move to give AI a visual language for science is more than just better graphics; it's a power grab reshaping scientific communication and data ownership.
The race for **xenotransplantation** just hit warp speed. But beyond the medical miracle, who really controls the future of **organ shortage solutions**?
Forget the hype. Deep analysis of CRISPR-based Cellgorithm technology reveals the hidden power struggle and true timeline for this cell programming revolution.
The Netherlands is lifting its ban on surplus embryo research. This isn't just science news; it’s a seismic shift in bioethics and the future of human enhancement.